Abstract
Diabetes affects approximately 246 million people worldwide and this number is
increasing. The IDF predict 380 million diabetics by 2025. The Global Diabetes
drug treatment market was valued at over $21 billion in 2006 and the market is
still expanding rapidly due to the high prevalence of diabetes and lifestyle
changes. You cannot afford to ignore this market. To ignore this report when
your competitors are reading it, would be a mistake. I urge you to read this
report today.
Do you know what the prevalence of diabetes will be in 2007 to 2025? Will the
oral anti-diabetics drugs and insulins still dominate the diabetes market
until 2012? Which regions will be the main sales generator contributing sales
into diabetes market? In addition, do you know what the drivers and restraints
of the market are? This report explains just how this market will experience
growth over the medium term future. This report not only reveals this, but
also examines the key player' s strategies used to maximize profits and R&D as
well as the relevant studies and trials. The new technologies for
anti-diabetic treatment will be also illustrated in this report.
Analysis in the report looks at the 7 major markets, aswell as the leading 7
expanding markets:
7 Major markets
- US
- Japan
- France
- Germany
- Italy
- Spain
- UK
- E7 (expanding markets)
- China
- India
- Indonesia
- Turkey
- Mexico
- Brazil
- Russia
In the year 2000, the global retail sales of diabetes drugs was US$8.1 billion
- the market has tripled in 6 years - Do you have as large a segment of that
market as you want? What is the revenue for oral anti-diabetics compared to
insulin - this report tells you.
In 2000 visiongain predicted that the retail market for diabetes medications
would exceed US$20 billion annually by 2006 - we were right. If you want to
know the shape and direction of the market in 2012 and 2025, you should order
visiongain' s Diabetes Market report now.
This report is arranged to provide you with in-depth analysis of the diabetes
drug market accompanied by forecasts by product type, country and application.
Information on the leading diabetes drugs for the treatment of type 1 and 2
diabetes as well as a brief look at the drugs for treating the complications
associated with diabetes will be presented in this report.
Forecasts of the market and an analysis of products in the worldwide
prescriptions market will provide a basis for understanding the significance
of past developments and future possibilities within this therapeutic
category. The main areas of pharmaceutical developments within the diabetes
market are delivery technologies for treatment of type 1 diabetes and drugs
for the treatment of type 2 diabetes.
Market figures regarding the current value of the diabetes drug market is
taken from the most recently available data of the global pharmaceutical
industry.
Key Market for the Future
In this report the treatments of diabetes will be examined in terms of the
classification of drugs, the current markets and sales forecasts for leading
drugs as well as new block busters.
According to the findings of this new 164+ page report, visiongain reveals
that oral anti-diabetic therapies are set to dominate the market over the
forecast period (2007-2012); insulin therapies will also expand rapidly.
Visiongain predicts that the diabetes market will continue to show significant
growth for what is an already large market. New blockbusters: Januvia, Galvus,
Byetta and Levemir will bring significant sales into diabetes market.
Actos and Lantus are existing leading products for oral anti-diabetic drugs
and insulin. However, are there any others which can compete with this for
market share or beat its dominance? This report answers that question with an
analysis of other players in the market.
View Cart
